Here we report that genetic ablation or pharmacological inhibition of IL-6 partially reverses Mφ-mediated GBM immunosuppression but does not sensitize GBM to anti-PD-1/CTLA-4 treatment. Here, CTLA4 is linked to glioblastoma.